AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18398154
Drug: bexarotene 400
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: bexarotene 400 mg/m(2)/d with cisplatin/vinorelbine
Trial: 15125904
Drug: Montelukast (Singulair)
RxNorm normalized name: montelukast Chewable Tablet [Singulair]
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast (Singulair) 10 mg daily for two menstrual cycles
Trial: 15125904
Drug: Ibuprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200 mg tablets) as needed
Trial: 11515643
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health care education (OHCE) for nursing home caregivers
Trial: 9763500
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A-hepatitis B vaccine administered at 0, 1, and 6 months
Trial: 28631050
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion rate titrated to keep ANI monitoring values between 50–70 (Group ANI, n: 22)
Trial: 28631050
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion rate regulated according to hemodynamic parameters (Group control, n: 22)
Trial: 28475555
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine with 2 μg/ml fentanyl
Trial: 28475555
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine with 2 μg/ml neostigmine
Trial: 28475555
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine with 4 μg/ml neostigmine
Trial: 28475555
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine with 8 μg/ml neostigmine
Trial: 21364505
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with 2.5 ng mL(‐1) of remifentanil (low‐remifentanil group)
Trial: 21364505
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with 5.0 ng mL(‐1) of remifentanil (high‐remifentanil group)
Trial: 16488434
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine continuous infusion for 120 hours
Trial: 16488434
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution continuous infusion for 120 hours
Trial: 3530032
Drug: Sustained-release terbutaline
RxNorm normalized name: terbutaline Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release terbutaline 7.5 mg
Trial: 28737261
Drug: Integrative cognitive‐behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative cognitive‐behavioural therapy for PGD (PG‐CBT)
Trial: 27707827
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg daily for 2 years)
Trial: 22856254
Drug: Wool underwear
RxNorm normalized name: sheep wool preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wool underwear (treatment group)
Trial: 21189769
Drug: 10% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sodium hypochlorite gel
Trial: 15955465
Drug: Step‐One‐Diet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step‐One‐Diet plus glucomannan in gelatine capsules
Trial: 1910798
Drug: Ephedrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (10 mg IV bolus injections)
Trial: 1910798
Drug: Phenylephrine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (80 microgram IV bolus injections)
Trial: 31887309
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg + metformin 1700 mg daily + lifestyle
Trial: 31887309
Drug: metformin 1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 1700 mg daily + lifestyle
Trial: 29112512
Drug: Antibiotic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic administration postincision
Trial: 29112512
Drug: Antibiotic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic administration preincision
Trial: 29112512
Drug: Nonadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadministration of antibiotics
Trial: 29112512
Drug: Antibiotics provided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics provided before incision
Trial: 22452536
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml reciprocating procedure device (RPD) mechanical syringe
Trial: 22452536
Drug: 60 ml
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ml vacuum syringe
Trial: 19890774
Drug: Venlafaxine extended
RxNorm normalized name: Desvenlafaxine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine extended release (dosage not specified)
Trial: 18260957
Drug: Valsartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (160 mg o.d.)
Trial: 18260957
Drug: Fluvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (80 mg o.d.)
Trial: 18260957
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Valsartan and Fluvastatin
Trial: 15821899
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity pulsed ultrasound therapy for 20 min daily for 6 weeks
Trial: 15821899
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity pulsed ultrasound therapy
Trial: 1359139
Drug: Captopril treatment
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril treatment (mean daily dose 69.1 mg)
Trial: 3913160
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy (tamoxifen, fluorouracil, vincristine, methotrexate, cyclophosphamide, mitoxantrone)
Trial: 26920994
Drug: 4 ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ± 1 calendar days of antibiotics
Trial: 26920994
Drug: Maximum of
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum of 10 calendar days of therapy
Trial: 22723577
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure therapy (systolic <120 mmHg)
Trial: 22723577
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure therapy (systolic <140 mmHg)
Trial: 10392325
Drug: Bosentan 100
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 100 mg
Trial: 10392325
Drug: Bosentan 200
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 200 mg
Trial: 10392325
Drug: Bosentan 500
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 500 mg
Trial: 10392325
Drug: Bosentan 1000
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 1000 mg
Trial: 10392325
Drug: Bosentan 500
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 500 mg (with additional IV doses)
Trial: 10392325
Drug: Bosentan (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (doses above 500 mg)
Trial: 10392325
Drug: Bosentan (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (oral treatment phase)
Trial: 8922245
Drug: Anthracycline-containing single,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-containing single, alternating or 'hybrid' combination chemotherapy regimens
Trial: 8922245
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality regimens with chemotherapy and radiation therapy
Trial: 1858176
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg indometacin
Trial: 1858176
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment with 250 mg naproxen b.i.d.
Trial: 29551226
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of quadrivalent HPV vaccine (Gardasil™)
Trial: 29551226
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of quadrivalent HPV vaccine (Gardasil™)
Trial: 29551226
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of quadrivalent HPV vaccine (Gardasil™)
Trial: 19922703
Drug: Topical hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hydrocortisone
Trial: 10624823
Drug: Scopolamine hydrobromide,
RxNorm normalized name: Scopolamine Hydrobromide, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide, 0.3 mg, i.v.
Trial: 10624823
Drug: Glycopyrrolate, 0.2
RxNorm normalized name: Glycopyrrolate, 0.2 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate, 0.2 mg, i.v.
Trial: 8538922
Drug: Isradipine 10
RxNorm normalized name: isradipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 10 mg daily for 1 week
Trial: 1934868
Drug: Folate supplementation
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate supplementation (1 mg/day) during methotrexate therapy
Trial: 30734207
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg subcutaneously every 2 weeks (Q2W), with dose increase to 150 mg Q2W at week 12 if LDL-C was >= 70 mg/dl
Trial: 26259809
Drug: RSV F
RxNorm normalized name: Respiratory syncytial virus fusion protein.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV F vaccine (60 or 90 µg) with or without aluminum phosphate adjuvant, 1 or 2 doses
Trial: 24101715
Drug: Immediate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate therapy group using the 'Exploring Feelings' manual (Attwood, 2004) for seven weekly sessions.
Trial: 24101715
Drug: Delayed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed therapy group (control).
Trial: 22436198
Drug: Acyclovir (herpes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (herpes simplex virus-suppressive therapy)
Trial: 19473149
Drug: Vibration stimulus
RxNorm normalized name: Limulus polyphemus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration stimulus during local anaesthetic injections
Trial: 19473149
Drug: No vibration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vibration stimulus during local anaesthetic injections
Trial: 19473149
Drug: Infiltration anaesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration anaesthetic injection with vibration
Trial: 19473149
Drug: Block anaesthetic
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Block anaesthetic injection with vibration
Trial: 16980070
Drug: Anti-IL-2R monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-IL-2R monoclonal antibody (n = 50)
Trial: 11200745
Drug: Opiate abusers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opiate abusers (group II) after treatment
Trial: 11200745
Drug: Opiate abusers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opiate abusers (group II) before and after treatment
Trial: 11200745
Drug: Alcohol abusers
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol abusers (group I) before treatment
Trial: 6487441
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 4 ml in 8% glucose
Trial: 6487441
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 4 ml in 5% glucose
Trial: 6487441
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 4 ml in 0% glucose (glucose-free solution)
Trial: 6487441
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 4 ml in hyperbaric solutions (8% and 5% glucose)
Trial: 31113718
Drug: Cord blood
RxNorm normalized name: CORD BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord blood sampling (5 mL from the placental end of the umbilical cord)
Trial: 26237827
Drug: Combined Traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Traditional Chinese Medicine (TCM) therapy including shenfu injection (60 mL) and deproteinized calf blood injection (DCBI) (1.2 g) for Yang-Qi deficiency; shenmai injection (60 mL) and DCBI (1.2 g) for Yin-Qi deficiency, once daily for 21 days.
Trial: 26237827
Drug: Aricept (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aricept (5 mg, once daily)
Trial: 19845435
Drug: bifendate (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bifendate (three times daily for 14 days)
Trial: 2647124
Drug: Short contact
RxNorm normalized name: BenzePrO Short Contact 9.8 % Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short contact dithranol in stiff emulsifying ointment base
Trial: 2647124
Drug: Stiff emulsifying
RxNorm normalized name: diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stiff emulsifying ointment
Trial: 29767639
Drug: Tenofovir (TFV)
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir (TFV) reduced-glycerin 1% gel applied vaginally for 14 days
Trial: 29767639
Drug: Tenofovir (TFV)
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir (TFV) reduced-glycerin 1% gel applied rectally for 14 days
Trial: 29767639
Drug: Cervicovaginal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervicovaginal lavage fluid and rectal fluid collected 24 hours after dosing
Trial: 28098723
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (ERM and ILM removal)
Trial: 26525473
Drug: Physiological solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological solution (group 1)
Trial: 26525473
Drug: 0.05% xylometazoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% xylometazoline solution (group 2)
Trial: 26525473
Drug: 10% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lidocaine solution (group 3)
Trial: 11128825
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid effervescent 1000 mg
Trial: 31147972
Drug: Initial loading
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial loading dose of 0.6 μg kg‐1 dexmedetomidine, followed by continuous infusion of 0.2 μg kg‐1 h‐1 (Group D, n=25)
Trial: 19085526
Drug: Internet‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet‐ and email‐based treatment programme for social phobia (Shyness programme)
Trial: 19085526
Drug: Cost-effectiveness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-effectiveness of Internet treatment
Trial: 16335199
Drug: Plum-blossom needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plum-blossom needle therapy combined with cupping
Trial: 9808914
Drug: Saffron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (50 mg dissolved in 100 ml of milk, administered twice a day)
Trial: 7695315
Drug: Quinine-clindamycin combination
RxNorm normalized name: clindamycin, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine-clindamycin combination regimen
Trial: 7695315
Drug: Quinine-doxycycline combination
RxNorm normalized name: quinine, combinations with psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine-doxycycline combination regimen
Trial: 7695315
Drug: Quinine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine monotherapy
Trial: 37852
Drug: Oxprenolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (20 mg)
Trial: 21771709
Drug: Neoadjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant systemic therapy with irinotecan, oxaliplatin, and cetuximab
Trial: 17086891
Drug: Modified-release clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release clarithromycin 1000mg once daily (AECMR)
Trial: 17086891
Drug: Immediate-release clarithromycin
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release clarithromycin 500mg twice daily (AECIR)
Trial: 16343235
Drug: TEC (Epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEC (Epirubicin 60 mg/m² iv + Paclitaxel 175 mg/m² 3 h iv + Carboplatin AUC 5)
Trial: 16343235
Drug: TC (Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC (Paclitaxel 175 mg/m² 3 h iv + Carboplatin AUC 5)
Trial: 2149704
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA) 200 mg/day for 6 months
Trial: 29086063
Drug: Glasdegib 100
RxNorm normalized name: glasdegib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib 100 mg diHCl formulation (fasted)
Trial: 29086063
Drug: Glasdegib 100
RxNorm normalized name: glasdegib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib 100 mg small-particle size maleate formulation (fasted)
Trial: 29086063
Drug: Glasdegib 100
RxNorm normalized name: glasdegib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib 100 mg large-particle size maleate formulation (fed)
Trial: 29086063
Drug: Glasdegib 100
RxNorm normalized name: glasdegib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib 100 mg large-particle maleate formulation (fasted) with rabeprazole
Trial: 29086063
Drug: Glasdegib 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib 50 mg oral solution (fasted)
Trial: 12952499
Drug: ABI 007
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI 007 260 mg/m(2) administered as a 30-minute infusion without steroid pretreatment
Trial: 12952499
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m(2) administered over 3 hours with steroid pretreatment
Trial: 11023500
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy and autografting
Trial: 1423182
Drug: GMCSF administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMCSF administered subcutaneously (SC) at 5 micrograms/kg twice daily for 14 days starting the day after chemotherapy
Trial: 1423182
Drug: GMCSF administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMCSF administered SC at 10 micrograms/kg daily for 20 days starting 2 days after chemotherapy
Trial: 1423182
Drug: GMCSF administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMCSF administered SC every 12 hours for 14 days
Trial: 1423182
Drug: Prechemotherapy priming
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prechemotherapy priming with GMCSF twice daily for 4 days (days -6 to -3)
Trial: 1423182
Drug: GMCSF administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMCSF administered SC at 5 micrograms/kg twice daily
Trial: 1423182
Drug: Moderate-dose GMCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose GMCSF with antihistamines and ibuprofen
Trial: 6374679
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g nabumetone twice daily
Trial: 30386143
Drug: LVLC-CTU (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVLC-CTU (80 kVp and 240 mgI/mL) with IR
Trial: 30386143
Drug: Conventional CTU
RxNorm normalized name: ACCESS,ADAPTER CHAIT C#CTU-10.0-18-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional CTU (120 kVp and 350 mgI/mL) with filtered-back projection
Trial: 27154481
Drug: Shared decision-making
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shared decision-making (SDM) via a multifaceted strategy (decision aid, support of IVF nurse, reimbursement for an extra treatment cycle)
Trial: 22629840
Drug: 89Sr-chloride fractional
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 89Sr-chloride fractional injection (50 Mbk)